Study Comparing Divarasib with Sotorasib or Adagrasib for Treating Advanced KRAS G12C-positive Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed by surgery.
• The cancer must have worsened during or after one to three previous treatments.
• Have at least one tumor that can be measured by scans.
• Have a KRAS G12C mutation in the cancer cells.
• Be able to provide a sample of the tumor tissue for testing.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.

Exclusion Criteria

• Have an allergy to divarasib, sotorasib, or adagrasib.
• Have a condition that affects the absorption of medications in the stomach or intestines.
• Have another active cancer-causing mutation.
• Have a mixed type of lung cancer that includes small-cell or large cell neuroendocrine cancer.
• Have untreated or active cancer that has spread to the brain or spinal cord.
• Have cancer in the membranes surrounding the brain or spinal cord.
• Have uncontrolled fluid buildup around the lungs, heart, or abdomen that needs frequent drainage.
• Have an infection that could affect safety or have been treated with antibiotics within 14 days before starting the study.
• Have previously been treated with any KRAS G12C or pan-KRAS/RAS inhibitors.
• Have received more than 30 Gy of radiation to the lungs within 6 months before starting the study.
• Have uncontrolled pain related to the tumor.
• Have unresolved side effects from previous cancer treatments.
• Have had another cancer within the last 5 years, except for certain non-threatening cancers.